MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors

Files

hdl_141565.pdf (788.38 KB)
  (Published version)

Date

2024

Authors

Sweeney, C.J.
Hainsworth, J.D.
Bose, R.
Burris, H.A.
Kurzrock, R.
Swanton, C.
Friedman, C.F.
Spigel, D.R.
Szado, T.
Schulze, K.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Journal of Clinical Oncology, 2024; 42(3):258-265

Statement of Responsibility

John D. Hainsworth, Ron Bose, Christopher J. Sweeney, Charles Swanton, Claire F. Friedman, David R. Spigel, Howard A. Burris, Razelle Kurzrock, Tania Szado, Katja Schulze, Richard Price, Julia Malato, Amy A. Lo, Funda Meric-Bernstam

Conference Name

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondaryanalyses arenotyetavailable.Clinical TrialUpdatesprovideanopportunitytodisseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The MyPathway multiple-basket study (ClinicalTrials.gov identifier: NCT02091141) is evaluating targeted therapies in nonindicated tumors with relevant molecular alterations. We assessed pertuzumab 1trastuzumab ina tissue-agnostic cohort of adult patients with human epidermal growth factor receptor 2 (HER2)–amplified and/or–overexpressed and/or–mutated solid tumors. The primary end point was objective response rate (ORR); secondary end points included survival and safety. At data cutoff (March 2022), 346 patients with HER2 amplification and/or overexpression with/without HER2 mutations (n 5 263), or HER2 mutations alone (n 5 83) had been treated. Patients with HER2 amplification and/or overexpression had an ORR of 25.9% (68/263, 95% CI, 20.7 to 31.6), including five complete responses (urothelial [n 5 2], salivary gland [n 5 2], and colon [n 5 1] cancers). Activity was higherinthosewithwild-type(ORR,28.1%)versusmutatedKRAS(ORR,7.1%).Amongpatients with HER2 amplification, ORR wasnumerically higher in patients with immunohistochemistry (IHC)31(41.0%;32/78)or21(21.9%;7/32),versus11(8.3%;1/12)ornoexpression(0%;0/20). InpatientswithHER2mutationsalone,ORRwas6.0%(5/83,95%CI,2.0to13.5).Pertuzumab1 trastuzumab showed activity in various HER2-amplified and/or-overexpressed tumors with wild-type KRAS, withtherange ofactivity dependent on tumor type,buthadlimitedactivity in the context of KRAS mutations, HER2 mutations alone, or 0-11 HER2 expression.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

© 2023 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

License

Grant ID

Call number

Persistent link to this record